New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:04 EDTARNAArena Pharmaceuticals and Eisai announce results of Lorcaserin Phase 2 trial
Arena Pharmaceuticals and Eisai announced that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin was recently published in the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Belviq is a serotonin 2C receptor agonist approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTARNABofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use